The unvaccinated has less than 1% chance of getting COVID.
Here are the numbers from the study.
Comirnaty (BNT162b2, Pfizer-BioNTech) COVID-19 Vaccine
The Pfizer-BioNTech, now called Comirnaty, COVID-19 vaccine was first given Emergency Use Authorization (EUA) on December 11, 2020, and as of May 10, 2021, has been approved for patients 12 years and older and has been administered to over 205 million Americans.3,4 On August 23, 2021, Comirnaty became the first FDA-approved COVID-19 vaccine for patients 16 years and older.4 This recommendation came from results of a phase 2/3 ongoing multinational, placebo-controlled, observer-blinded, trial of Comirnaty. Primary end points were efficacy of the vaccine against laboratory-confirmed COVID-19 and safety. A total of 43,548 participants (≥ 16 years) from 152 sites worldwide were randomized 1:1 to receive 2 doses, 21 days apart, of either placebo or Comirnaty (30 μg/dose).5 The primary efficacy end point was achieved in 8 patients in the Comirnaty group (0.04%) and
162 patients in the placebo group (0.88%). This corresponds with the vaccine being 95% effective in preventing COVID-19 (95% CI, 90.3%-97.6%).5
Clinical testing of COVID-19 vaccine efficacy has led to the first FDA-approved COVID-19 vaccine, Comirnaty.
www.pharmacytimes.com